Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Vinay Prasad has returned to the FDA as the Chief of the Center for Biologics Evaluation and Research, just 10 days after his mysterious departure. His return comes after a short "vacation" in California, and it is believed that the regulator convinced him to come back. Some speculate that Prasad's time away may have helped him gain a better understanding of the complexities involved in decision-making at the FDA, especially when it comes to ensuring the safety of patients and meeting the needs of various stakeholders. This unexpected turn of events has generated interest and optimism among industry insiders.Gilead remains positive about the prospects of its HIV prevention drug, despite uncertainties surrounding recommendations from the U.S. Preventive Services Task Force. The FDA has launched a new program to help pharmaceutical companies lower regulatory barriers to manufacturing in the U.S. Other news includes Dewpoint Therapeutics slashing headcount, Novartis rumored to be taking over RNA specialist Avidity, and Trilink Biotechnologies offering process development services for nucleic acid therapeutic development. Lotte Biologics is expanding its global manufacturing bases, while other companies like Bicycle, Tune, and Iovance are downsizing to conserve cash. The FDA is in flux, Pfizer is discussing pricing with Trump, and Merck is cutting jobs. Vertex's next-generation pain drug failed in trials despite strong Q2 earnings. Thank you for listening to Pharma and Biotech daily: your source for quick updates on the latest news in the pharmaceutical and biotechnology industries.